Express News | Ping An Securities Pharmaceutical Industry 2025 Annual Strategy Report: Exploring new growth from payment sources, focusing on innovation, going overseas, equipment upgrades, and Consumer recovery.

BreakingsDec 15 12:17

This week's Hong Kong stock bull | The "first domestic makeup stock" in Hong Kong! Mao Ge Ping soared over 86% in its first week of listing; Consumer encouragement policies are expected to continue to strengthen, and Lao Pu Gold has increased by over 20%.

This week, the Hang Seng Index increased by 0.53%, closing at 19,971.24 points; during the same period, the Hang Seng TECH Index rose by 0.33%, closing at 4,479.6 points; the Hang Seng China Enterprises Index increased by 0.7%, closing at 7,186.59 points.

Futu NewsDec 14 11:52

HUTCHMED (China) to Receive $10 Million Milestone Payment From Takeda After First European Reimbursement for Fruzaqla

MT NewswiresDec 13 12:23

Hutchmed (China) (00013.HK) will receive a milestone payment of 10 million dollars from its partner.

Hutchmed (China) (00013.HK) announced that it will receive a milestone payment of $10 million from its partner Takeda (TAK.US). Takeda secured FRUZAQLA in Spain this December for treatment recommendations of previously treated metastatic colorectal cancer patients to be included in the public medical insurance coverage, marking the first recommendation for such inclusion in Europe. The announcement stated that FRUZAQLA received approval from the European Commission in June this year. Takeda holds the global exclusive rights for further development, commercialization, and production of furmonertinib outside of mainland China, Hong Kong, and Macau.

AASTOCKSDec 13 08:23

Hutchmed (China) (00013.HK): Following the first inclusion of FRUZAQLA (fruquintinib) in the healthcare insurance in Europe, a milestone payment from Takeda will be received.

Gelonghui reports on December 13 that Hutchmed (China) (00013.HK) announced it will receive a $10 million milestone payment from its partner Takeda (TSE: 4502/NYSE: TAK). Takeda has received a recommendation in December 2024 for FRUZAQLA to be included in public medical coverage for patients with previously treated metastatic colorectal cancer in Spain, marking the first recommendation for public medical coverage obtained in Europe. Colorectal cancer is the second leading cause of cancer-related deaths in Europe. FRUZAQLA received approval from the European Commission in June 2024.

Gelonghui FinanceDec 13 08:04

HUTCHMED Secures Breakthrough Therapy Designation in China for Lung Cancer Drug Combination

MT NewswiresDec 12 17:02